Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | PSMB1 | P20618 | 8/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.42 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.42 |
| ▸ | PDE1A | P54750 | 3/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7597037 | 1.00 | ESR1 (0.56) | ESR1ESR2LTA4HPSMB1PSMB5 | |
| SCHEMBL7603643 | 0.99 | ESR1 (0.55) | ESR1ESR2LTA4HPSMB1PSMB5 | |
| SCHEMBL7603606 | 0.99 | ESR1 (0.55) | ESR1ESR2LTA4HPSMB1PSMB5 | |
| SCHEMBL7704155 | 0.88 | ESR1 (0.46) | ESR1ESR2LTA4HPSMB1PSMB5 | |
| SCHEMBL7704151 | 0.83 | ESR1 (0.42) | ESR1ESR2LTA4HPSMB1PSMB5 | |
| SCHEMBL7597060 | 0.78 | ESR1 (0.47) | ESR1ESR2PSMB1PSMB5PDE1A | |
| SCHEMBL7597047 | 0.78 | ESR1 (0.47) | ESR1ESR2PSMB1PSMB5PDE1A | |
| SCHEMBL7602287 | 0.77 | ESR1 (0.46) | ESR1ESR2PSMB1PSMB5CYP19A1 | |
| SCHEMBL7602301 | 0.77 | ESR1 (0.46) | ESR1ESR2PSMB1PSMB5CYP19A1 | |
| SCHEMBL7597039 | 0.77 | ESR1 (0.89) | ESR1ESR2LTA4HPSMB1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020161007-A1 | Non-steroidal modulators of estrogen receptors | PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2002-10-31 | — | — | US | claimed |
| WO-2002066415-A2 | NON-STEROIDAL MODULATORS OF ESTROGEN RECEPTORS | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2002-08-29 | — | — | WO | claimed |
| US-20020161007-A1 | Non-steroidal modulators of estrogen receptors | PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161007-A1 | Non-steroidal modulators of estrogen receptors | ESRRB, ESR2, ESRRG | ESR1 6/4885ESR2 2/4885LTA4H 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.